Is Sun Pharmaceutical Industries a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Sun Pharmaceutical Industries Ltd is a good quality company .

Is Sun Pharmaceutical Industries undervalued or overvalued?

The key valuation ratios of Sun Pharmaceutical Industries Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Sun Pharmaceutical Industries share price return in the past 10 years?

Sun Pharmaceutical Industries Ltd share price has appreciated 7.9% annually (CAGR) over the past ten years.

Is Sun Pharmaceutical Industries a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Sun Pharmaceutical Industries Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

What is the P/E ratio of Sun Pharmaceutical Industries?

The latest standalone P/E ratio of Sun Pharmaceutical Industries as of 04-Dec-2024 is 160.42.

What is the P/B ratio of Sun Pharmaceutical Industries?

The latest standalone P/B ratio of Sun Pharmaceutical Industries as of 04-Dec-2024 is 18.29.

What is the 52-week high and low of Sun Pharmaceutical Industries?

The 52-week high of Sun Pharmaceutical Industries is Rs. 1960.20 and the 52-week low is Rs. 1209.00.

What is the TTM revenue of Sun Pharmaceutical Industries?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Sun Pharmaceutical Industries is Rs. 19974.06 (Cr.).

Sun Pharmaceutical Industries Ltd - Stock Valuation and Financial Performance

Name: Sun Pharmaceutical Industries
Brand: Sun Pharmaceutical Industries

BSE: 524715 | NSE: SUNPHARMA | Pharmaceuticals & Drugs | Large Cap

Place order

Sun Pharma Inds. Share Price

₹1,796 -2.60 -0.14%
as on 04-Dec'24 13:51

10 Year X-Ray of Sun Pharma Inds.:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	25.1%	18.6%	21.5%	8.4%	8.7%	10.1%	5.7%	9.3%	17.2%	17.6%	-
Value Creation Index ⓘ	1.2	0.7	0.9	-0.3	-0.2	-0.1	-0.5	-0.2	0.5	0.6	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	27,392	28,109	31,308	26,416	29,066	32,838	33,498	38,654	43,886	48,497	49,759
Sales YoY Gr.	-	2.6%	11.4%	-15.6%	10%	13%	2%	15.4%	13.5%	10.5%	-
Adj EPS ⓘ	22.5	22.1	27.8	11.3	15.1	16.4	24.5	27.4	36.7	42	46.1
YoY Gr.	-	-1.8%	25.9%	-59.3%	33.4%	8.6%	49.8%	11.9%	33.7%	14.4%	-
BVPS (₹) ⓘ	123.5	137	152.7	159.7	172.6	188.7	193.7	200.1	233.4	265.4	288.1
Adj Net Profit ⓘ	4,653	5,311	6,664	2,712	3,616	3,925	5,882	6,579	8,797	10,065	11,054
Cash Flow from Ops. ⓘ	5,616	6,686	7,082	3,907	2,196	6,555	6,170	8,985	4,959	12,135	-
Debt/CF from Ops. ⓘ	1.6	1.3	1.4	2.7	4.8	1.3	0.6	0.1	1.3	0.2	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	6.6%	10.8%	13.1%	10.5%
Adj EPS ⓘ	7.2%	22.7%	19.6%	14.4%
BVPSⓘ	8.9%	9%	11.1%	13.7%
Share Price	7.9%	32.3%	33.7%	45.8%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	21.1	18.1	19.1	7.2	9.1	9.1	12.8	13.9	16.9	16.8	16.7
Op. Profit Mgn % ⓘ	29.2	30.8	31	21.1	22.1	21.3	25.3	26.5	26.8	26.8	28
Net Profit Mgn % ⓘ	20.5	22.9	24.1	12.1	14.3	13.2	15.7	17.4	20.2	20.9	22.2
Debt to Equity ⓘ	0.4	0.3	0.3	0.3	0.3	0.2	0.1	0	0.1	0	0
Working Cap Days ⓘ	189	242	239	163	154	148	146	136	219	206	161
Cash Conv. Cycle ⓘ	54	83	85	17	27	48	49	44	110	97	99

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 16.60%

Sales growth is growing at healthy rate in last 3 years 13.13%

Net Profit is growing at healthy rate in last 3 years 19.62%

Sales growth is not so good in last 4 quarters at 9.11%

Latest Financials - Sun Pharmaceutical Industries Ltd.

	Standalone	Consolidated
TTM EPS (₹)	11.2	46.1
TTM Sales (₹ Cr.)	19,974	49,759
BVPS (₹.) ⓘ	98.3	288.1
Reserves (₹ Cr.) ⓘ	23,353	68,875
P/BV ⓘ	18.29	6.24
PE ⓘ	160.42	39.04

From the Market
52 Week Low / High (₹)	1209.00 / 1960.20
All Time Low / High (₹)	1.65 / 1960.20
Market Cap (₹ Cr.)	4,31,544
Equity (₹ Cr.)	239.9
Face Value (₹)	1
Industry PE ⓘ	44.7

Management X-Ray of Sun Pharma Inds.:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

4.04

2.53

1.92

1.78

2.29

2.44

2.05

1.07

0.79

* Pledged shares as % of Promoter's holding (%)

Valuation of Sun Pharma Inds.

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Sun Pharma Inds.

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	27,392	28,109	31,308	26,416	29,066	32,838	33,498	38,654	43,886	48,497
Operating Expenses ⓘ	19,543	19,950	21,626	20,881	22,792	25,863	25,030	28,773	32,298	35,748
Manufacturing Costs	1,922	3,754	3,882	4,018	3,979	3,928	4,082	2,583	2,767	2,947
Material Costs	6,733	6,170	8,164	7,352	7,869	9,230	8,690	10,352	10,662	10,663
Employee Cost	4,503	4,204	4,312	4,708	5,298	5,704	6,126	7,301	8,296	9,429
Other Costs ⓘ	6,385	5,822	5,268	4,803	5,646	7,002	6,132	8,537	10,573	12,709
Operating Profit ⓘ	7,849	8,158	9,682	5,535	6,274	6,974	8,468	9,882	11,588	12,749
Operating Profit Margin (%)	28.7%	29.0%	30.9%	21.0%	21.6%	21.2%	25.3%	25.6%	26.4%	26.3%
Other Income ⓘ	566	658	1,030	912	1,059	652	859	1,437	694	1,628
Interest ⓘ	579	523	400	518	555	303	141	127	172	238
Depreciation ⓘ	1,195	1,038	1,265	1,500	1,753	2,053	2,080	2,144	2,529	2,557
Exceptional Items ⓘ	-238	-685	0	-951	-1,214	-261	-4,306	-4,567	-171	-494
Profit Before Tax ⓘ	6,403	6,571	9,048	3,479	3,810	5,010	2,799	4,481	9,408	11,088
Tax ⓘ	915	914	1,212	911	601	823	515	1,076	848	1,439
Profit After Tax	5,488	5,657	7,836	2,568	3,209	4,187	2,285	3,406	8,561	9,648
PAT Margin (%)	20.0%	20.1%	25.0%	9.7%	11.0%	12.8%	6.8%	8.8%	19.5%	19.9%
Adjusted EPS (₹)	21.9	18.9	29.0	8.7	11.1	15.7	12.1	13.6	35.3	39.9
Dividend Payout Ratio (%)	14%	5%	12%	23%	25%	25%	62%	73%	33%	34%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	25,582	32,977	36,637	38,314	41,409	45,264	46,463	48,011	55,995	63,667
Share Capital ⓘ	207	241	240	240	240	240	240	240	240	240
Reserves ⓘ	25,374	32,736	36,397	38,074	41,169	45,025	46,223	47,771	55,755	63,427
Minority Interest	2851	4085	3791	3884	3314	3860	3017	3055	3320	3439
Debt	7,596	8,316	8,091	9,752	9,893	7,578	3,343	698	5,958	2,846
Long Term Debt	1,368	3,110	1,436	1,772	1,523	2,029	898	230	0	1
Short Term Debt	6,228	5,206	6,655	7,980	8,371	5,549	2,445	469	5,958	2,844
Trade Payables	3,287	3,583	4,395	4,766	4,148	3,584	3,974	4,490	5,682	5,653
Others Liabilities ⓘ	7,656	3,420	6,003	5,393	3,375	4,791	7,314	10,704	6,269	5,754
Total Liabilities ⓘ	46,972	52,381	58,917	62,109	62,139	65,077	64,110	66,958	77,225	81,359
Fixed Assets
Gross Block	20,407	22,180	24,466	26,949	31,687	35,116	35,579	38,707	43,100	44,284
Accumulated Depreciation	7,724	6,308	6,791	8,096	9,851	12,269	14,026	16,042	19,035	21,072
Net Fixed Assetsⓘ	12,682	15,872	17,675	18,853	21,837	22,847	21,553	22,665	24,065	23,211
CWIP ⓘ	2,039	2,175	2,801	2,465	1,411	1,220	1,567	1,287	4,973	5,354
Investmentsⓘ	2,716	1,830	1,192	7,143	7,903	10,143	9,612	12,849	14,824	15,026
Inventories	5,668	6,423	6,833	6,881	7,886	7,875	8,997	8,925	10,513	9,868
Trade Receivables	5,106	6,776	7,203	7,815	8,884	9,421	9,061	10,485	11,439	11,249
Cash Equivalents	10,998	13,182	15,141	9,929	7,276	6,488	6,446	5,033	5,770	10,521
Others Assetsⓘ	7,762	6,124	8,073	9,023	6,943	7,083	6,874	5,715	5,640	6,130
Total Assets ⓘ	46,972	52,381	58,917	62,109	62,139	65,077	64,110	66,958	77,225	81,359

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	5,616	6,686	7,082	3,907	2,196	6,555	6,170	8,985	4,959	12,135
PBT ⓘ	6,403	6,571	9,048	3,479	3,810	5,010	2,799	4,481	9,408	11,088
Adjustment ⓘ	774	1,857	501	1,382	1,969	1,993	1,810	1,975	2,723	1,554
Changes in Working Capital ⓘ	180	247	-409	-212	-2696	899	2564	1559	-5662	1062
Tax Paid ⓘ	-1,740	-1,988	-2,057	-742	-886	-1,346	-1,003	969	-1,510	-1,569
Cash Flow From Investing Activity ⓘ	-2,866	-4,372	-4,222	-3,371	-681	-2,589	536	-5,725	-7,944	-690
Capex	-2,300	-3,333	-3,590	-1,894	-3,162	-1,450	-1,073	-1,434	-2,065	-2,171
Net Investments	-324	-410	-873	-677	1,752	-1,702	1,373	-3,791	-1,644	932
Others ⓘ	-242	-629	242	-800	729	563	236	-499	-4,235	548
Cash Flow From Financing Activityⓘ	-1,187	-1,889	-2,285	-1,539	-2,731	-5,715	-5,980	-5,193	2,376	-6,710
Net Proceeds from Shares ⓘ	75	9	2	1	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	-350	-301	-334	-477	-461	-272	-144	-73	-132	-219
Dividend Paid ⓘ	-310	-724	-243	-813	-1,326	-1,399	-1,586	-2,159	-2,520	-2,901
Others ⓘ	-601	-872	-1,711	-250	-945	-4,044	-4,250	-2,961	5,028	-3,590
Net Cash Flow ⓘ	1,563	426	575	-1,003	-1,215	-1,749	726	-1,934	-608	4,735

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	24.89	19.32	22.51	6.85	8.05	9.66	4.98	7.21	16.46	16.13
ROCE (%)	25.06	18.64	21.48	8.4	8.68	10.07	5.66	9.28	17.24	17.6
Asset Turnover Ratio	0.74	0.57	0.57	0.85	0.91	0.93	0.95	1.03	0.61	0.61
PAT to CFO Conversion(x)	1.02	1.18	0.9	1.52	0.68	1.57	2.7	2.64	0.58	1.26
Working Capital Days
Receivable Days	48	76	81	54	54	56	55	53	91	85
Inventory Days	58	77	77	49	48	48	50	49	81	77
Payable Days	125	203	178	227	207	153	159	149	174	194

Sun Pharmaceutical Industries Ltd Stock News

Sun Pharmaceutical Industries Ltd FAQs

What is the share price of Sun Pharma Inds.?

Company share prices are keep on changing according to the market conditions. The closing price of Sun Pharma Inds. on 04-Dec-2024 13:51 is ₹1,796.

What is the market cap of Sun Pharma Inds.?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2024 13:51 the market cap of Sun Pharma Inds. stood at ₹4,31,544.4.

What is the P/E ratio of Sun Pharma Inds.?

The latest P/E ratio of Sun Pharma Inds. as of 04-Dec-2024 13:51 is 160.4.

What is the P/B ratio of Sun Pharma Inds.?

The latest P/B ratio of Sun Pharma Inds. as of 04-Dec-2024 13:51 is 18.29.

What is the 52-week high and low of Sun Pharma Inds.?

The 52-week high of Sun Pharma Inds. is ₹1,960.2 and the 52-week low is ₹1,209.

What is the TTM revenue of Sun Pharma Inds.?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Sun Pharma Inds. is ₹19,974 ( Cr.) .

About Sun Pharmaceutical Industries Ltd

Sun Pharmaceutical Industries established in 1983 with five psychiatry products and a two person marketing team. Sun Pharma is the fifth largest specialty generic pharmaceutical company in the world. It provide high-quality, affordable medicines trusted by healthcare professionals and patients in many countries worldwide. Sun Pharma is also India’s largest and pharmaceutical company. Its global presence is supported by several manufacturing facilities across few continents. In the US market which contributes a significant share of its revenues, the company is the leader in the generic dermatology segment. It has strong capabilities in developing generic and complex products with a robust pipeline of many ANDAs, including high value First-to-File (FTF) opportunities. It has an established presence in Europe and key high-growth Emerging Markets (EM) like Russia, Romania, South Africa, Brazil and Malaysia. The company’s primary focus is to in-license generic and differentiated generic products that are close to commercialization or in advanced stage of development for North America, Western Europe and Japan markets.

The company is market leader in India and it is interested in partnerships for late stage and/or marketed opportunities complementary to its commercial footprint or expansion within its core areas of focus in India. These include CNS disorders, Cardiology, Diabetes and Metabolic disorders, Gastroenterology, Ophthalmology, Oncology, Pain, Rheumatology, Allergy, Asthma and Inflammation and Gynecology. Its focus is for NCEs, NBEs, NDDS based differentiated products, Biosimilars, Proprietary Technology Barrier Products which provide it the first mover advantage in India. The company’s leadership position in India allows it to offer significant value to innovator companies who want to partner with a dynamic and leading company, capable of successfully marketing its assets and willing to give the right priority to in-licensed or partnered projects.

Business area of the company

The company is among the largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business and a skilled team enables it to deliver high-quality products, trusted by customers and patients in many countries across the world, at affordable prices.

Products

Formulations
Active Pharmaceutical Ingredients - Crams
OTC

Awards

2005: Dilip Shanghvi is named Entrepreneur of the Year (Healthcare and Life Science) Ernst & Young.
2007: Dilip Shanghvi is recognised as First Generation Entrepreneur of the Year CNBC-TV18.
2007: Dilip Shanghvi wins Pharmaceutical Companies IMC Juran Quality Medal IMC Ramkrishna Bajaj National Quality Award Trust.
2008: Sun Pharma wins Outstanding Exporter of the Year: Pharmaceuticals, Healthcare and Lifesciences Award CNBC TV 18:The International Trade Awards.
2008: Sun Pharma receives Business Leadership Award NDTV Profit.
2008: Dilip Shanghvi is named CEO of the Year Business Standard.
2008: Dilip Shanghvi is honoured with Entrepreneur of the Year Award The Economic Times.
2009: Sudhir V. Valia is named Best CFO in Pharma and Healthcare CNBC-TV18 CFO Awards.
2009: Sun Pharma receives Rolta Corporate Award: Pharmaceuticals Dun & Bradstreet.
2010: Dilip Shanghvi receives Entrepreneur of the Year Award Ernst & Young.
2010: Sun Pharma receives Business Leadership of the Year Award NDTV PROFIT.
2011: Dilip Shanghvi is recognised as World Entrepreneur of the Year Ernst & Young.
2011: Dilip Shanghvi is honoured with Businessman of the Year Award Business India.
2011: Dilip Shanghvi is named Indian of the Year (Business) CNN IBN.
2011: Sudhir V. Valia is named Best CFO in Pharma and Healthcare CNBC-TV18 CFO Awards.
2011: Sun Pharma is hailed as the Pharmaceutical Company of the Year Frost & Sullivan India Healthcare Excellence Awards.
2012: Sun Pharma is named Most Outstanding Company of the Year CNBC-TV18 India Business Leader Awards.
2012: Sun Pharma is listed among The World’s 100 Most Innovative Companies Forbes.
2012: Sun Pharma is listed in Asia's Fab 50 Companies Forbes.
2012: Sun Pharma wins Business Leadership of the Year - Pharmaceutical Award NDTV Profit.
2013: Uday Baldota receives Best CFO in Pharma and Healthcare Award CNBC TV-18 CFO Awards.
2013: Sun Pharma is named Company of the Year The Economic Times.
2013: Sun Pharma is named Company of the Year Business Standard.
2013: Sun Pharma is listed among Asia's Fab 50 Companies Forbes.
2014: Dilip Shanghvi receives Entrepreneur of the Year Award Forbes Magazine.
2014: Sun Pharma receives Cardiovascular Pharmaceutical Company of the Year Award Frost & Sullivan India Healthcare Excellence Awards.
2014: Dilip Shanghvi receives Business Leader of the Year Award The Economic Times.
2014: Sun Pharma is listed among The World’s 100 Most Innovative Companies Forbes.
2014: Dilip Shanghvi receives JRD TATA Corporate Leadership Award All India Management Association.
2015: Dilip Shanghvi receives Business Leader of the Year Award NDTV.
2015: Sun Pharma receives Excellence in CSR Award “India Pharma Awards - 2015” instituted by UBM-India.
2015: Sun Pharma receives India Pharma Research & Development Award 2015 Ministry of Chemicals & Fertilizers, Government of India.
2016: Sun Pharmaceutical Industries Inc. receives DIANA (Distribution Industry Award for Notable Achievements) Award Healthcare Distribution Alliance, USA.
2016: Dilip Shanghvi receives Padma Shri Award Government of India.
2016: Sun Pharma receives Community Care Award ASSOCHAM (Associated Chambers of Commerce).
2017: Dilip Shanghvi receives Entrepreneur of the Year Award All India Management Association (AIMA).
2018: Dilip Shanghvi receives Lifetime Outstanding Achievement Award Indore Management Association (IMA).
2018: Sun Pharma receives Outstanding Contribution in CSR Federation of Gujarat Industries.
2018: Sun Pharma receives Best CSR Practices The Economic Times (ET).

Milestones

Establishment & Growth

1983: The Company established with five psychiatry products and a two person marketing team
1994: The Company lunches IPO
1996: The Company expands sales network across 24 countries.
2007: The Company demerges Sun Pharma Advanced Research Company (SPARC) into a separate entity becoming the first pure research company to be listed on India Stock Exchanges.
2013: Ranbaxy acquisition catapults Sun Pharma to world’s 5th largest specialty generic pharmaceutical company.

Acquisitions & Alliances

1996: The Company acquires API plant from Knoll Pharma at Ahmednagar, Maharashtra, India.
1997: The Company purchases equity stakes in TDPL and MJ Pharma.
1997: The Company’s first international acquisition of Caraco Pharmaceutical Laboratories, USA.
1999: The Company acquires Milmet Labs and Gujrat Lyka Organics, India.
2000: The Company acquires Pradeep Drug Company, India.
2004: The Company acquires Phlox Pharma (India) and niche brands from Women’s First Healthcare (US).
2005: The Company completes buyout of manufatruing unit in Bryan, Ohio, US.
2005: The Company acquires ICN’s business in Hungary from Valent Pharma.
2005: The Company acquires intellectual property and assets of Able Labs from US District Bankruptcy court in New Jersey.
2008: The Company acquires Chattem Chemicals Inc, US.
2010: The Company acquires controlling stake in Israel-based Taro Pharmaceuticals, USA to effectively double company’s US businesses.
2012: The Company completes two more acquisitions in USA; Dusa Pharmaceuticals and the generic business of URL Pharmaceuticals.
2014: The Company acquires Ranbaxy in a $4 billion landmark transaction to create world’s fifth largest specialty generic pharma company.
2014: The Company acquires pharmalucence in USA.
2015: The Company acquires GSK’s Opiates business in Australia
2015: The Company acquires Insite Vision Inc. to strighthen branded ophthalmic portfolio in USA.
2016: Sun Pharma acquires 14 brands from Novartis in Japan
2016: Sun Pharma acquires Ocular Technologies, Sarl to strengthen branded ophthalmic portfolio
2016: Sun Pharma acquires branded oncology product Odomzo (sonidegib) from Novartis for global markets
2016: Sun Pharma acquires Biosintez to enhance presence in Russian market

Research & Manufacturing

1983:Sun Pharma sets up compact manufacturing facility for tablets and capsules at Vapi, Gujarat
1991: Sun Pharma establishes first research centre to create a base for strong product and process development
1991: Ranbaxy establishes state-of-the-art manufacturing facility for Cephalosporins at Mohali, Punjab, India
1995: Sun Pharma begins production at API manufacturing plant in Panoli, Gujarat, India.
1997: Sun Pharma establishes new research facility in Mumbai, India
1998: Sun Pharma begins operations at a new formulation unit in Silvassa, Gujarat, India
2001: Sun Pharma commences production at new formulations unit in Dadra, India
2004: Sun Pharma sets up new formulation unit in Jammu, India
2004: Sun Pharma commissions first joint venture manufacturing unit in Dhaka, Bangladesh
2015: Sun Pharma enters into research collaboration with Weizmann Institute of Science, Israel & Health Research Institute of Santiago, Spain for brain therapies
2016: International Centre for Genetic Engineering and Biotechnology (ICGEB) & Sun Pharma sign an exclusive agreement to develop novel botanical drug for treatment of Dengue
2017: Sun Pharma & National Institute of Virology (NIV), India sign agreement to fight Zika, Chikungunya and Dengue

Products & Innovations

1987: Sun Pharma begins sale of products across India
1988: Sun Pharma launches Monotrate and Angizem, first cardiology products that are sold till today
1989: Sun Pharma introduces gastroenterology products in India
1998: Sun Pharma acquires a basket of products from Natco Pharma
2014: Sun Pharma and Merck & Co. Inc. enter into licensing agreement for Tildrakizumab (MK-3222)
2016: Sun Pharma launches Imatinib Mesylate in USA
2016: Sun Pharma launches first branded ophthalmic product, BromSite in USA